| Effects of SGLT2 inhibitors on systemic and tissue low-grade inflammation: The potential contribution to diabetes complications and cardiovascular disease |
43 |
| Beneficial effects of SGLT2 inhibitors on fatty liver in type 2 diabetes: A common comorbidity associated with severe complications |
27 |
| Morning administration of 0.4 U/kg/day insulin glargine 300 U/mL provides less fluctuating 24-hour pharmacodynamics and more even pharmacokinetic profiles compared with insulin degludec 100 U/mL in type 1 diabetes |
24 |
| Diabetic retinopathy, a vascular and inflammatory disease: Therapeutic implications |
20 |
| Burden of diabetes, hyperglycaemia in China from to 2016: Findings from the 1990 to global burden of disease study |
18 |
| Comparative efficacy, safety, and cardiovascular outcomes with once-weekly subcutaneous semaglutide in the treatment of type 2 diabetes: Insights from the SUSTAIN 1-7 trials |
15 |
| The application of simple metrics in the assessment of glycaemic variability |
14 |
| Early worsening of diabetic retinopathy after rapid improvement of blood glucose control in patients with diabetes |
14 |
| Digital diabetes: Perspectives for diabetes prevention, management and research |
14 |
| Role of myokines in the development of skeletal muscle insulin resistance and related metabolic defects in type 2 diabetes |
12 |
| Effects of glucose-lowering agents on surrogate endpoints and hard clinical renal outcomes in patients with type 2 diabetes |
12 |
| Clinical perspectives from the BEGIN and EDITION programmes: Trial-level meta-analyses outcomes with either degludec or glargine 300 U/mL vs glargine 100 U/mL in T2DM |
11 |
| Risks of diabetic foot syndrome and amputation associated with sodium glucose co-transporter 2 inhibitors: A Meta-analysis of Randomized Controlled Trials |
11 |
| Resveratrol reduces albuminuria in diabetic nephropathy: A randomized double-blind placebo-controlled clinical trial |
11 |
| A dietary intervention with functional foods reduces metabolic endotoxaemia and attenuates biochemical abnormalities by modifying faecal microbiota in people with type 2 diabetes |
10 |
| Comparing SGLT-2 inhibitors to DPP-4 inhibitors as an add-on therapy to metformin in patients with type 2 diabetes: A systematic review and meta-analysis |
9 |
| MicroRNAs from urinary extracellular vesicles are non-invasive early biomarkers of diabetic nephropathy in type 2 diabetes patients with the 'Asian Indian phenotype' |
9 |
| Inhibitory role of oxytocin on TNF alpha expression assessed in vitro and in vivo |
9 |
| Glucocentric risk factors for macrovascular complications in diabetes: Glucose 'legacy' and 'variability'-what we see, know and try to comprehend |
9 |
| Risk of bone fracture associated with sodium-glucose cotransporter-2 inhibitor treatment: A meta-analysis of randomized controlled trials |
8 |
| SGLT2 inhibitors and incretin agents: Associations with alanine aminotransferase activity in type 2 diabetes |
8 |
| Therapy with cholesteryl ester transfer protein (CETP) inhibitors and diabetes risk |
8 |
| Association between PNPLA3rs738409 polymorphism decreased kidney function in postmenopausal type 2 diabetic women with or without non-alcoholic fatty liver disease |
8 |
| Practical implementation, education and interpretation guidelines for continuous glucose monitoring: A French position statement |
8 |
| Non-targeted metabolomic biomarkers and metabotypes of type 2 diabetes: A cross-sectional study of PREDIMED trial participants |
8 |
| Association between non-alcoholic fatty liver disease and bone turnover biomarkers in post-menopausal women with type 2 diabetes |
8 |
| Intensive lifestyle modifications with or without liraglutide 3 mg vs. sleeve gastrectomy: A three-arm non-randomised, controlled, pilot study |
7 |
| Complement activation in patients with diabetic nephropathy |
7 |
| SGLT2 inhibition and glucagon secretion in humans |
7 |
| Trajectories of fasting plasma glucose variability and mortality in type 2 diabetes |
7 |
| Glycaemic variability is associated with severity of coronary artery disease in patients with poorly controlled type 2 diabetes and acute myocardial infarction |
6 |
| Weight gain in early pregnancy and risk of gestational diabetes mellitus among Latinas |
6 |
| Timing of insulin basal rate reduction to reduce hypoglycemia during late post-prandial exercise in adults with type 1 diabetes using insulin pump therapy: A randomized crossover trial |
6 |
| Association between non-alcoholic fatty liver disease and decreased lung function in adults: A systematic review and meta-analysis |
6 |
| Obesity paradox in associations between body mass index and diabetes-related hospitalization and mortality in patients with type 2 diabetes: Retrospective cohort studies |
6 |
| Carbamylation is a competitor of glycation for protein modification in vivo |
6 |
| Degree of ketonaemia and its association with insulin resistance after dapagliflozin treatment in type 2 diabetes |
6 |
| Efficacy and safety of combination therapy with SGLT2 and DPP4 inhibitors in the treatment of type 2 diabetes: A systematic review and meta-analysis |
6 |
| Serum levels of osteopontin predict diabetes remission after bariatric surgery |
6 |
| Fenofibrate decreases plasma ceramide in type 2 diabetes patients: A novel marker of CVD? |
5 |
| Complement deposition on renal histopathology of patients with diabetic nephropathy |
5 |
| Impact of different timing of consuming sweet snack on postprandial glucose excursions in healthy women |
5 |
| Diabetes-related cardiomyopathy: The sweet story of glucose overload from epidemiology to cellular pathways |
5 |
| Indications for islet or pancreatic transplantation: Statement of the TREPID working group on behalf of the Societe francophone du diabete (SFD), Societe francaise d'endocrinologie (SFE), Societe francophone de transplantation (SFT) and Societe francaise de nephrologie - dialyse - transplantation (SFNDT) |
5 |
| Haemoglobin A1c and 5-year all-cause mortality in French type 2 diabetic patients aged 70 years and older: The GERODIAB observational cohort |
5 |
| Holistic psychosocial determinants of adherence to medication in people with type 2 diabetes |
5 |
| Diabetes and dyslipidaemia are associated with oxidative stress independently of inflammation in long-term antiretroviral-treated HIV-infected patients |
5 |
| Metabolomics signatures associated with an oral glucose challenge in pregnant women |
5 |
| Plasma fetuin-B concentrations are associated with insulin resistance and first-phase glucose-stimulated insulin secretion in individuals with different degrees of glucose tolerance |
4 |
| Consuming snacks mid-afternoon compared with just after lunch improves mean amplitude of glycaemic excursions in patients with type 2 diabetes: A randomized crossover clinical trial |
4 |
